Antigen Sensitised Dendritic Tumor Vaccine Kills Brain Tumor
Researchers in the cytology laboratory, Beijing Institute of Neurosurgery, Beijing Tiantan Hospital adopting the technique of antigen peptide extraction by micro-acid elution of tumor cells, prepared the dendritic cell tumor vaccine and used it in experimental study. A remarkable killing effect was observed against C6 tumor cells resulting in large area of tumor cell necrosis in the tumor carrying animals. Dr. Liu Fusheng et al. made an approach with the dendritic cells which were the strongest specific antigen presenting cells then added GM-CSF and IL-4 to the bone marrow of the rats for culture of the dendritic cells. Micro-acid elution technique was used for the extraction of in vitro antigen sensitised dendritic cells to establish the animal models of cerebral C6 glioma; the antigen sensitised dendritic cells were used in vivo for the observation of the effects on cerebral tumors; additionally, activity detection of CTL was done by in vitro culture of spleen T cells from the sensitised animals with the addition of the C6 tumor antigen and IL-2..
The results revealed that at the 8th day of the culture, typical dendritic cells were seen; double labelling with immunohistochemical methods showed OX4 and OX52 positive cells; flow-cytometric analysis revealed the positive rate of OX62 being 93.03 % and OX6
92.01 %; the in vitro cytotoxicity test showed that the killing effect of C6 tumor cells was remarkable in rats immunized with antigen sensitised dendrite cells and killing effect was observed in the animals without being treated with the antigen sensitised dendritic cells. Pathological studies showed that large areas of necrosis were present in the tumor tissues of the experimental group, with the area of necrosis accounted for 51 %, and in the controls, there was only small areas of necrosis accounting for only 6 %, giving a significant statistical difference (P<0.01). The researchers also discovered that the survival period could be as long as 60 days without tumor growth and in the controls the survival period was only 11 days, indicating the therapeutic effect of the antigen sensitised dendritic cell tumor vaccine for
intra-cerebral glioma., 百拇医药
The results revealed that at the 8th day of the culture, typical dendritic cells were seen; double labelling with immunohistochemical methods showed OX4 and OX52 positive cells; flow-cytometric analysis revealed the positive rate of OX62 being 93.03 % and OX6
92.01 %; the in vitro cytotoxicity test showed that the killing effect of C6 tumor cells was remarkable in rats immunized with antigen sensitised dendrite cells and killing effect was observed in the animals without being treated with the antigen sensitised dendritic cells. Pathological studies showed that large areas of necrosis were present in the tumor tissues of the experimental group, with the area of necrosis accounted for 51 %, and in the controls, there was only small areas of necrosis accounting for only 6 %, giving a significant statistical difference (P<0.01). The researchers also discovered that the survival period could be as long as 60 days without tumor growth and in the controls the survival period was only 11 days, indicating the therapeutic effect of the antigen sensitised dendritic cell tumor vaccine for
intra-cerebral glioma., 百拇医药